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ABSTRACT
Methylation of lysine residues on the tails of histone
proteins is a major determinant of the transcription
state of associated DNA coding regions. The inter-
play among methylation states and other histone
modifications to direct transcriptional outcome
is referred to as the histone code. In addition to
histone methyltransferases and demethylases
which function to modify the methylation state of
lysine sidechains, other proteins recognize specific
histone methylation marks essentially serving as
code readers. While these interactions are highly
specific with respect to site and methylation state
of particular lysine residues, they are generally
weak and therefore difficult to monitor by traditional
assay techniques. Herein, we present the design and
implementation of a homogeneous, miniaturizable,
and sensitive assay for histone methylation-
dependent interactions. We use AlphaScreen, a
chemiluminescence-based technique, to monitor
the interactions of chromodomains (MPP8, HP1b
and CHD1), tudor domains (JMJD2A) and plant
homeodomains (RAG2) with their cognate
trimethyllysine histone partners. The utility of the
method was demonstrated by profiling the binding
specificities of chromo- and tudor domains toward
several histone marks. The simplicity of design and
the sensitive and robust nature of this assay should
make it applicable to a range of epigenetic studies,
including the search for novel inhibitors of
methylation-dependent interactions.
INTRODUCTION
Regulation of gene expression is closely tied to post-
translational modiﬁcations of histones. Several types of
covalent histone modiﬁcations have been identiﬁed,
including acetylation, phosphorylation, ubiquitination,
sumoylation and methylation (1). The spectrum and coor-
dination of these post-translational modiﬁcations has been
proposed to dictate transcriptional activity and down-
stream cellular processes, giving rise to the ‘histone code’
hypothesis (2). Methylation of lysine has been of particu-
lar interest due to its slow turnover in vivo and association
with several disease phenotypes, including cancer (3,4).
At least six lysine residues are methylated in the core
histones H3 and H4. The lysine residues can be mono-,
di- or tri-methylated, thus adding another layer of
complexity. Whereas acetylation generally leads to
transcriptional activation, the physiological outcome of
histone methylation is more ambiguous. For example,
H3K4me2 is a signature of actively transcribed genes,
while H3K9 methylation is a hallmark of constitutive
heterochromatin (5,6). Methylation itself is not suﬃcient
to eﬀect changes in transcriptional activity (7), indicating
the need for coordination with eﬀector or recognition
proteins. Speciﬁc domains have been identiﬁed in
chromatin-associated proteins that bind to methylated
Lys of histones H3 or H4 in a site- and degree-speciﬁc
manner. These domains include chromodomains, tudor
domains, plant homeodomain (PHD) modules and
ankyrin repeats (3,8–14). Proteins harboring these
modules may function to recruit chromatin remodeling
and histone-modifying proteins, stabilize chromatin
complexes, or directly aﬀect chromatin structure (1).
These ‘readers’ of the post-translational modiﬁcations
are gaining attention as potential therapeutic targets for
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of a speciﬁc protein–protein interaction at a covalently
modiﬁed histone residue is a potentially more attractive
target than inhibition of the enzymes that may pro-
miscuously add or remove these modiﬁcations at more
than one histone residue.
Several methods have been used to detect binding of
epigenetic partners, including ﬂuorescence spectroscopy
(15), ﬂuorescence polarization (FP; 16) and ﬂuorescence
resonance energy transfer (FRET) (17). While these are
established methods, they generally require large sample
sizes and/or are subject to interference and high back-
ground levels that make them diﬃcult to use with the
low-aﬃnity interactions of methyl-binding domains with
Kd values in the micromolar range (18–20). Surface
plasmon resonance (SPR) (21) has the advantage in its
ability to detect low-aﬃnity interactions but it is severely
restricted in its high-throughput capabilities. In vitro pull-
down assays have been used to identify binding of protein
domains to post-translationally modiﬁed histone peptides.
This technique was modiﬁed to increase throughput as
a CADOR (chromatin-associated domain array) chip
(13). The CADOR chip is useful for initial screens of
binding partners, but for high-throughput screening
(HTS) it is limited by its qualitative nature, requirement
for multiple wash steps and the expense of production.
Here, we introduce a simple, homogeneous method
for measuring binding of epigenetic partners using
AlphaScreen technology. AlphaScreen is a colloidal
bead-based assay founded on luminescent oxygen chan-
neling chemistry (22). This format is ﬂexible and may be
utilized by multiple assay paradigms, including detection
of protein–protein interactions (23). The homogeneous,
sensitive and scalable AlphaScreen assay presented here
is an appropriate method to measure binding of covalently
modiﬁed peptides to a wide range of histone-associated
proteins. We present the design and optimization of
binding assays for chromodomains CHD1, MPP8 and
HP1b, as well as for the JMJD2A tudor domains, and
the PHD domain of RAG2. Furthermore, the assay was
used to interrogate the binding speciﬁcity of the above
domains to a series of peptides representing various
methylation states and methyllysine loci.
MATERIALS AND METHODS
General reagents
Assay buﬀer consisted of PBS, pH 7.4, containing 0.01%
Tween-20. Microplates used were 384- or 1536-well white
solid-bottom type from Greiner Bio-One (Monroe, NC).
Peptides were synthesized by the Tufts Medical
School Department of Physiology Core Facility (Boston,
MA, USA). AlphaScreen detection was performed with
PerkinElmer Glutathione S-Transferase (GST) and
Histidine (Nickel Chelate) Detection Kits (Waltham,
MA, USA).
Histone-binding proteins
Mouse heterochromatin protein 1-beta (NM_007622)
chromodomain-containing region of amino acids 1–185
was expressed as a recombinant protein with N-terminal
GST tag (GST-HP1b). Human M-phase phosphoprotein
(NM_017520) chromodomain-containing region of amino
acids 50–120 was expressed as a recombinant protein with
either an N-terminal GST tag (GST-MPP8) or N-terminal
His6 tag (His-MPP8). Human chromodomain-containing
protein, Y-linked, 2B (NM_001001722) chromodomain-
containing region of amino acids 5–101 was expressed as
a recombinant protein with N-terminal GST tag (GST-
CDY2B). Human chromodomain helicase DNA-binding
protein 1 (NM_001270) chromodomain-containing region
of amino acids 251–467 was expressed as a recombinant
protein with N-terminal GST tag (GST-CHD1). Human
jumonji domain containing 2A protein (NM_014663) was
expressed with an N-terminal His6 tag (His-JMJD2A)
from amino acids 890–1031 to include the double
tudor domain. Human recombination activating gene 2
(NM_000536) PHD-containing region of amino acids
397–493 was expressed as a recombinant protein with
N-terminal GST tag (GST-RAG2).
AlphaScreen assay in 384-well format
A 2-fold dilution series of biotinylated glutathione
S-transferase (b-GST), ﬁnal 0.1–50nM, was plated in a
384-well plate. Dilutions of b-GST were incubated with
20mg/ml streptavidin-conjugated donor and anti-GST
acceptor beads for 30min at room temperature. Samples
were read in an EnVision Multilabel Plate Reader
(PerkinElmer, Waltham, MA, USA) using the 384 Plate
HTS AlphaScreen aperture (35-ms excitation time, 100-ms
measurement time), and values were corrected with an
internal crosstalk optimization.
A panel of chromodomain proteins was assayed to
measure binding of trimethylated histone H3 peptides.
Chromodomain proteins, tagged with N-terminal GST,
were incubated at a ﬁnal concentration of 100nM with
100nM biotinylated-H3 peptide trimethylated at either
Lys4 or Lys9 (b-H3K4me3 or b-H3K9me3, respectively).
Reactions were incubated for 30min at room temperature
in 384-well plates in a volume of 30ml. AlphaScreen
streptavidin-conjugated donor and anti-GST acceptor
beads (10ml) were added to wells at a ﬁnal concentration
20mg/ml and incubated for 10min at room temperature.
Plates were read in the EnVision reader as described above.
Assay miniaturization
GST-HP1b was incubated at a ﬁnal concentration of
100nM with either b-H3K4me3 or b-H3K9me3 peptides
(ﬁnal 20–200nM). Incubations in 384-well plates consisted
of 30-ml samples. Following a 30min incubation of protein
and peptide at room temperature, 10ml of AlphaScreen
streptavidin-conjugated donor and anti-GST acceptor
beads (ﬁnal 20mg/ml each) were added to sample wells
and incubated for 10min. Plates were read in an
EnVision microplate reader as previously described.
Complementary reactions in 1536-well plates were
achieved by employing a BioRAPTR (Beckman Coulter,
Fullerton, CA, USA) ﬂying reagent dispenser (FRD) for
automated addition of reagents. To each well, 0.2–2.0mlo f
biotinylated peptide was dispensed in combination with
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volume of 3ml. Plates were centrifuged for 1min at
1000r.p.m. and incubated at room temperature for
30min. AlphaScreen streptavidin-conjugated donor and
anti-GST acceptor beads were added in a 1mL FRD
dispense for ﬁnal 20mg/mL concentration of each bead.
Plates were centrifuged again for 1min at 1000r.p.m. and
incubated for 10min at room temperature. Samples were
measured with an EnVision multilabel plate reader
equipped with a 1536 Plate HTS AlphaScreen aperture
(80-ms excitation time, 240-ms measurement time),
and values were corrected with an internal crosstalk
optimization. Data are expressed as the mean of four
replicate measurements.
Peptide–protein binding matrices
Interactions of methyl-binding domain proteins with
trimethyllysine histone peptides were measured in matrix
titrations. The concentration of GST- or His-tagged
protein was varied from 5–1000nM as the concentration
of biotinylated peptide was varied from 10–1000nM.
Incubations were performed in duplicate in 384-well
plates for 30min at room temperature. AlphaScreen
streptavidin-conjugated donor and acceptor beads (anti-
GST and nickel-chelate acceptor beads for GST- and
His-tagged proteins, respectively) were added for ﬁnal
20mg/ml each bead and ﬁnal volume of 40ml. Samples
were incubated for 10min at room temperature and read
with an EnVision plate reader.
Competitive binding of unlabeled peptides in
1536-well plate format
Competition of biotinylated histone H3 peptides
with unlabeled peptides of varying sequence and post-
translational modiﬁcation was performed to measure the
speciﬁcity and aﬃnity of binding to chromatin-associated
domains. Proteins were preincubated with the correspond-
ing biotinylated peptide for 30min at room temperature.
Competitor peptide dilutions were plated in a 384-well
plate. A CyBi-Well (CyBio Inc., Woburn, MA) 384-
channel simultaneous pipettor was then used to transfer
3ml of peptide from the 384-well plate into an empty
1536-well plate in quadruplicate (ﬁnal 60nM–1mM
unlabeled peptide). Preincubated protein-peptide solution
was dispensed (1ml) into these wells with a BioRAPTR
FRD. Reactions were incubated at room temperature for
30min. AlphaScreen beads (1ml, ﬁnal 20mg/ml) were
dispensed and reactions were incubated for 10min prior
to an EnVision read. AlphaScreen signal (counts per
second, c.p.s.) was plotted versus log[Peptide, M] as the
mean of four replicates for each peptide concentration.
Nonlinear curve ﬁtting was carried out using Prism 4
software (GraphPad, La Jolla, CA, USA).
RESULTS
Assay principle and validation
The AlphaScreen assay we employ is a proximity-based
reporting system used to measure binding between
two cognate partners. As shown in Scheme 1, laser exci-
tation (680nm) of a donor bead releases a ﬂow of singlet
oxygen. Acceptor beads in close proximity (<200nm)
utilize this singlet oxygen to generate a narrow
chemiluminescent signal of 520–620nm. Donor and
acceptor beads are conjugated with functional groups
that allow bioconjugation with speciﬁc analytes. Here,
we have conﬁgured an AlphaScreen assay by using
streptavidin-coated donor beads and anti-GST antibody
coated acceptor beads to measure binding of a GST-
tagged chromodomain protein to a biotinylated histone
peptide.
Biotinylated-GST (b-GST) was titrated with 20mg/ml
streptavidin-conjugated donor beads and anti-GST
acceptor beads to validate AlphaScreen detection and
assess the signal window (Figure 1A). AlphaScreen
signal reached a maximum at 2nM b-GST of
25000c.p.s. Higher concentrations of b-GST decreased
the signal, the so-called ‘hook eﬀect’ (www.perkinelmer
.com) whereby b-GST concentration surpasses the
binding capacity of the AlphaScreen beads. Determining
where high concentrations of analyte lead to
nonproductive binding and loss of signal is essential in
the optimization of AlphaScreen assays.
To assess the applicability of the AlphaScreen format
to measure chromodomain interactions, initial bind-
ing studies were performed with 100nM GST-tagged
chromodomain proteins and 100-nM biotinylated-
histone H3 peptides that were trimethylated at either K4
or K9 (Figure 1B). All chromodomain proteins tested
showed selectivity for b-H3K9me3 over b-H3K4me3,
except for CDY2B where the assay signal was too low
to allow a deﬁnitive conclusion. These data are in agree-
ment with previous reports of HP1b selectivity (13,18,24),
while recognition of speciﬁc histone lysine methylation by
the MPP8 chromodomain has not been reported to date.
Under these conditions, GST-HP1b and GST-MPP8
also showed interaction with b-H3K4me3. The aﬃnity
of GST-MPP8 for b-H3K4me3 was greater than that
of GST-HP1b (26000 and 7800c.p.s., respectively).
However, selectivity for trimethylation at H3K9 versus
at H3K4 was greater for GST-HP1b than for GST-
MPP8, 3.3- versus 1.7-fold.
N
Methylated
Histone Peptide
GST-Tagged
Chromodomain
1O2
anti-GST Coated 
Acceptor Bead
Streptavidin Coated 
Donor Bead
Scheme 1. AlphaScreen assay of chromodomain protein binding to
methylated histone peptides.
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To determine the scalability of the assay, HP1b–b-
H3K4me3 and HP1b–b-H3K9me3 binding reactions
were performed in 384- and 1536-well microplates. A
range of both protein and peptide concentrations was
used. In both plate types, binding patterns were nearly
identical (Figure 2A and B). HP1b was again shown to
be selective for binding b-H3K9me3 over b-H3K4me3.
The hook eﬀect was observed in both 384- and 1536-
well plates at concentrations of b-H3K9me3 peptide
>50nM. These data indicate this AlphaScreen peptide–
protein-binding assay is amenable to HTS at the low
ﬁnal assay volume of 3ml per well.
MPP8 chromodomain assay optimization
Binding of H3K9me3 to the MPP8 chromodomain was
observed using a wide range of concentrations of
both GST-MPP8 (5–1000nM protein) and b-H3K9me3
(10–1000nM peptide) (Figure 3A). The ‘hook eﬀect’ was
observed at peptide concentrations >100nM, and at
protein concentrations >100nM GST-MPP8. We thus
selected 50nM peptide and 50nM GST-MPP8 to use in
our studies. To demonstrate the reporting capability
of the new assay, H3K9me3 peptide was titrated
into preincubated complex of 50nM GST-MPP8 and
b-H3K9me3 (Figure 3B). The unlabeled peptide displaced
binding of its cognate biotinylated peptide to the MPP8
chromodomain with an EC50 of 0.92mM.
To assess the generality of the chromodomain binding
assay initially developed with GST-tagged chromodomain
proteins, we replaced GST-MPP8 with its His6-tagged
version, His-MPP8, and measured its binding to
b-H3K9me3 by using nickel chelate-functionalized
acceptor beads. Titration of biotinylated-His6 revealed a
higher binding capacity for nickel-chelate acceptor beads
compared to anti-GST acceptor beads (data not shown).
As shown in Figure 3C, protein and b-H3K9me3 peptide
were titrated in 384-well plates. While AlphaScreen signal
was higher for His-MPP8, patterns were similar for both
protein tags. Titration of unlabeled H3K9me3 peptide
into preincubated complex of 10nM His-MPP8 and
50nM b-H3K9me3 resulted in displacement of bio-
tinylated peptide with an EC50 of 0.28mM (Figure 3D).
The observed 3-fold diﬀerence in EC50 values between
H3K9me3 competitions against the GST- and His6-based
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Figure 1. (A) Biotinylated-GST titration curve was used to identify
the ‘hook’ point of AlphaScreen assay. (B) Chromodomain proteins
CDY2B, HP1b, and MPP8 demonstrated binding selectivity for
biotinylated histone H3 peptides trimethylated at Lys9 over peptides
trimethylated at Lys4. GST-tagged proteins (100nM) were incubated
with either 100nM b-H3K4me3 (white) or b-H3K9me3 (black). Assay
background was low, as no signal was observed in the absence of
peptide (gray).
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Figure 2. AlphaScreen assay was miniaturized to a volume of 3ml/well
for high-throughput screening. Comparable binding of 20–200nM
b-H3K4me3 (squares) and b-H3K9me3 (circles) peptides to 100nM
GST-HP1b was observed in 384-well (A) and 1536-well (B) plate
formats. Data in 1536-well plate format (B) are shown as the mean
and standard deviation of four replicate measurements.
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ference in protein level in the assays and was within the
typical error of EC50 determination.
Application of assay to other trimethylated lysines
Thus far, we have demonstrated the assay for chromatin-
associated domains that target histones trimethylated
at K9. To investigate alternative methyllysine marks,
speciﬁcity of CHD1 chromodomain binding was investi-
gated using b-H3K4me3 and b-H3K9me3 peptides
(Figure 4A). AlphaScreen signal was 2-fold greater for
50nM GST-CHD1 interaction with 200nM peptides
trimethylated at H3K4 versus H3K9. Titration of GST-
CHD1 with b-H3K4me3 peptide in 1536-well plate
format conﬁrmed binding of the protein–peptide pair
(Figure 4B). No hook point was observed for the
b-H3K4me3 peptide in the concentration range
examined, but concentrations of CHD1 >50nM protein
resulted in decreased AlphaScreen signal. Unlabeled
H3K4me3 peptide displaced binding of its cognate
biotinylated peptide (200nM) to GST-CHD1 (20nM)
with an EC50 of 4.8mM (Figure 4C).
Extending the assay beyond chromodomains
The AlphaScreen assay described is applicable not
only to chromodomain proteins but also to all domains
that bind modiﬁed histones. Here, we demonstrate
that the double tudor domain-containing protein
JMJD2A binds a histone H3K4me3 peptide, in addi-
tion to a histone H4K20me3 peptide (Figure 5A). The
signal for b-H3K4me3 interaction leveled oﬀ around
100nM peptide, whereas the signal for b-H4K20me3
binding continued to increase in the concentration range
tested.
Binding of the JMJD2A/H3K4me3 epigenetic pair was
measured over a range of both peptide and protein
concentrations (Figure 5B). Conditions of 100nM His-
JMJD2A and 100nM b-H3K4me3 were selected for
peptide competition experiments following the observa-
tion of AlphaScreen hook points at 500nM protein
and 200nM peptide. Unlabeled H3K4me3 displaced
b-H3K4me3 peptide from the His-JMJD2A double
tudor domain with an EC50 of 5.5mM (Figure 5C).
Binding of histone methyllysine marks was also
examined with the PHD-domain containing protein
RAG2. Interaction of b-H3K4me3 with GST-tagged
RAG2 was measured in a matrix titration, using a wide
range of both protein and peptide concentrations
(Figure 5D). Concentrations of GST-RAG2 and
b-H3K4me3>5nM and 200nM, respectively, resulted in
decreased AlphaScreen signal. Unlabeled H3K4me3
competed with b-H3K4me3 (50nM) for binding to
GST-RAG2 (5nM) with an EC50 of displacement equal
to 6.3mM (Figure 5E).
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Figure 3. A range of GST-tagged MPP8 protein concentrations was titrated with 10–1000nM b-H3K9me3 peptide (A)( B) Unlabeled
H3K9me3 peptide competed with 50nM b-H3K9me3 for binding to 50nM GST-MPP8. (C) Binding of b-H3K9me3 to MPP8 was further validated
in an alternative AlphaScreen assay format where GST-tagged protein was replaced with His6-MPP8 in a matrix titration with 10–1000nM
b-H3K9me3. (D) Unlabeled H3K9me3 peptide competed with 50nM b-H3K9me3 for binding to 10nM His-MPP8 protein. Data are shown as
the mean and standard deviation of two or four replicate measurements for matrix titrations (A, C) and peptide competition assays (B, D),
respectively.
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With the assay at hand, we proceeded to investigate the
binding interactions of chromo- and tudor domains with
peptides representing key histone marks. Biotinylated and
trimethylated histone peptides, shown in Figure 6A, were
co-incubated with their GST- or His-tagged epigenetic
binding partner. EC50 values for displacement of
biotinylated H3K9me3 from a preformed complex with
GST-MPP8 were determined to be 0.94, 1.1 and 1.2mM
following 15-, 30- and 60-min incubations with unlabeled
peptide, respectively (Figure 6B). Biotinylated H3K4me3
interaction with His-JMJD2A was disrupted with EC50
values of 10.3, 11.1 and 11.3mM following 15-, 30- and
60-min incubations with unlabeled peptide, respectively
(Figure 6C). We selected an optimal incubation time
of 30min with unlabeled competitor peptides for use in
our studies.
Unlabeled peptides varied in sequence, methylation
state and methylation site were employed to displace
these interactions to measure speciﬁcity and relative
aﬃnities of binding. Unlabeled H3K9me3 peptide
displaced binding of its cognate biotinylated peptide,
b-H3K9me3, to MPP8 protein with an EC50 of 0.92mM
(Figure 6D, Table 1). While not a direct measure of
binding aﬃnity, this value is in the range of Kd values
reported for other chromodomain proteins (18–20). The
selectivity of MPP8 binding to histone H3K9me3 over
H3K4me3, observed in Figure 1B, was conﬁrmed here
with a higher EC50 of displacement measured with
H3K4me3 than with H3K9me3 (240mM and 0.92mM,
respectively). Furthermore, H4K20me3 was also ruled
out as a binding partner for MPP8. Finally, H3 and H4
peptides lacking methylation at Lys residues did not
signiﬁcantly disrupt MPP8 interaction with b-H3K9me3,
indicating MPP8 chromodomain binding is speciﬁc
for covalently modiﬁed histones. Interestingly, the
H3K9me2 peptide had approximately the same EC50
value as its trimethylated form (0.90mM and 0.92mM,
respectively). To our knowledge, this represents the ﬁrst
characterization of MPP8 binding of histone methyllysine
marks.
Peptide competition assays were also used to measure
binding of several histone peptides to the JMJD2A double
tudor domain protein (Figure 6E and Table 1). Unlabeled
H3K4me3 displaced its biotinylated form, b-H3K4me3,
with an EC50 of 5.5mM, the lowest value of the peptides
tested. In agreement with our previous observations
(Figure 5A), H4K20me3 displaced b-H3K4me3 by
competing for binding to His-JMJD2A (EC50 7.0mM).
H3K9me3 and H4K20me2 were also found to compete
eﬀectively for JMJD2A tudor binding with low EC50
values of 12mM. In contrast to the near-equal eﬀect of
H3K9me3 and H3K9me2 on MPP8 (Figure 6B and
Table 1), the same pair of peptides displayed very diﬀerent
competition capacity in the JMJD2A tudor assay, with the
trimethylated peptide showing 10-fold greater aﬃnity
than its dimethylated counterpart. Further, the JMJD2A
tudor domain displayed a greater discriminating power
against the lysine methylation state at the H3K9 locus
than it did against the H4K20 site. The rank order of
JMJD2A binding aﬃnity was H3K4me3>H4K20me3>
(H3K9me3, H4K20me2)>>(H3, H4, H3K9me2). These
data are largely in accordance with previous reports of
recognition of methylated histones by the JMJD2A
tudor domain (13,25,26).
DISCUSSION
Here, we describe the development and application of a
novel assay for detection of methyl-binding domain
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Figure 4. The assay for chromodomain binding of histones is applicable
to other trimethylated lysines. (A) GST-CHD1 (50nM) is selective for
binding b-H3K4me3 (white) compared to b-H3K9me3 (black). GST-
tagged CHD1 protein was titrated with 10–1000nM b-H3K4me3
peptide in duplicate measurements (B). Data are shown as the mean
and standard deviation for each peptide concentration. Unlabeled
H3K4me3 peptide competed with its cognate biotinylated peptide
(200nM) for interaction with 20nM CHD1 (C). Data are shown as the
mean and standard deviation of four replicate measurements.
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representing histone epigenetic marks and make use of
the common aﬃnity puriﬁcation tags existing on the
methyl-dependent protein binders to conﬁgure a homoge-
neous, sensitive and highly modular assay operating on
the AlphaScreen detection principle. Laser excitation
and chemiluminescent detection allow measurement of
low-aﬃnity interactions on the scale from Kd 1–50mM
observed for histone binding to chromodomain and
tudor domain proteins. This robust assay requires only
nanomolar concentrations of protein, a distinct advantage
over other techniques used to study similar peptide–
protein interactions. For example, FP measurements
require 0.1mM–1mM protein (20) and the direct depen-
dence of FP signal on the molar fraction of all ﬂuorescent
species present in the assay makes that technique incapa-
ble of detecting low-abundance bound ligand in the
presence of high-abundance unbound counterpart.
The data presented here indicate that this assay can be
used to study multiple post-translational modiﬁcations as
well as various methyl-binding domains. The assay was
initially demonstrated with GST-tagged chromodomains
and biotinylated histone H3 peptide trimethylated at Lys9,
b-H3K9me3. However, substitution of the functional GST
tag with an N-terminal His6-tag retained assay outcome,
thus validating its design and extending its scope beyond a
single aﬃnity tag. We demonstrated versatility of the
assay through chromodomain binding of other peptides,
b-H3K4me3 and b-H4K20me3. Finally, we performed the
assay with a JMJ2DA double tudor domain protein and a
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methyl-binding domains. Thus, it appears that the assay
is ﬂexible enough to allow its application to be extended
to additional methyl-dependent interactors, beyond the
domains studied here. The relative ease of conﬁguring
an AlphaScreen assay is in part due to the low sensitivity
of its signal strength to the location of the bead binding
sites, which is in contrast with FRET-based detection
schemes where a careful optimization of the label place-
ment positions is often required.
Our mechanistic study of chromodomain-binding
speciﬁcity involved multiple peptide competition assays
performed in a highly miniaturized format. As
anticipated, unlabeled H3K9me3 displaced its cognate
biotinylated peptide by competing for binding to the
MPP8 chromodomain. At the same time, an oﬀ-target
trimethylated peptide H4K20me3 failed to compete oﬀ
the cognate H3K9me3 peptide, further proving that the
present assay faithfully reports on the relevant domain–
histone interactions. Dimethylated peptide, H3K9me2,
was found to be a novel MPP8 binding partner, displacing
b-H3K9me3 with an EC50 approximately equal to that of
trimethylated peptide. Binding partners of the JMJD2A
double tudor domain were also investigated using
the present assay. JMJD2A tudor was found to bind
H3K4me3, H4K20me3 and, to a lesser extent, H3K9me3
and H4K20me2 and only marginally with H3K9me2 and
unmethylated histone peptides. We conclude that this
assay is capable of accurately mapping the binding of
chromatin-associated domains to methylated histone
peptides, as the proﬁling data obtained are in agreement
with previous reports (13,26).
The simple design and homogeneous nature of the assay
presented here should make it amenable to HTS for small
molecules that inhibit binding of chromatin-associated
proteins to methylated histones, as evidenced by its imple-
mentation here into a 1536-well format. Excitation at a
long wavelength and emission at a shorter wavelength
circumvents the high background encountered with
ﬂuorescence-based assays. Importantly, recent ﬂuores-
cence spectroscopic proﬁling of the National Institutes
of Health Chemical Genomics Center library, containing
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autoﬂuorescence with relatively small shifts (100nm) to
longer excitation wavelengths (27). In addition, the avail-
ability of dual-recognition AlphaScreen reagents (e.g.
biotinylated GST or biotinylated hexahistidine, which
bind to both the donor and acceptor beads) provides the
opportunity to perform an immediate counterscreen in
order to exclude possible false positives acting on the
detection system.
The past two decades have seen an explosion of
epigenetic-related clinical and molecular biological
discoveries, highlighted by the global hypomethylation
of DNA found in human tumors, hypermethylation of
tumor suppressor genes and inactivation of microRNA
genes by DNA methylation (28–30). Almost all cancers
show abnormal epigenetic features, and epigenetic
factors are commonly disrupted in debilitating mental
retardations. Early development, and subsequent suscep-
tibility to disease, is also in part regulated epigenetically
(31,32). Furthermore, the regulatory pathways that
underpin the maintenance of stem cell pluripotency also
rely on chromatin-based epigenetic memory systems.
Histone deacetylase and DNA methyltransferase
inhibitors are currently used in the clinic to treat various
cancers through reversal of tumor suppressor silencing
incurred in disease development (33). Histone methylation
became a target of epigenetic therapy following the asso-
ciation of lysine methyltransferase and demethylase
enzymes with cancer (25,34–36). Recently, mutations
and dysregulation of methyl-binding domains have been
identiﬁed as contributing to human disease (37).
Disruption of methyl-binding domain interactions at
speciﬁc methylated histone resides may represent the
future of epigenetic therapy. However, to fully exploit
the potential that epigenetics as a target area holds, our
understanding of underlying complexities, e.g. the
combinatorial nature of histone modiﬁcations, has to
increase. It is anticipated that the method described
here will be an important tool for the identiﬁcation
of epigenetic interactions and the discovery of small
molecules to be used as chemical probes or starting
points for drug discovery.
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